Literature DB >> 7855230

Effects of accumbens DALA microinjections on brain stimulation reward and behavioral activation in intact and 6-OHDA treated rats.

P L Johnson1, J R Stellar.   

Abstract

The effects of bilateral nucleus accumbens microinjections of d-ala-met-enkephalinamide (DALA) were assessed in behavioral activation and lateral hypothalamic self-stimulation (LHSS) rate-frequency curve-shift paradigms in normal and accumbens 6-OHDA (4.0 micrograms) treated rats. Microinjections of DALA (2.5 micrograms/microliters) in the behavioral activation paradigm had little effect on normal activity; however, DALA administered to 6-OHDA treated rats produced a significant overall increase in locomotion. The 6-OHDA DALA-induced locomotion effect peaked at 2 weeks after 6-OHDA treatment and then returned to baseline levels by week 5 post-treatment. Using LHSS, DALA tested over a range of doses (2.5, 5, 10, 20 micrograms/microliters) displayed a weak biphasic reward effect only at the highest dose, which was characterized by an initial suppression followed by an elevation. DALA significantly depressed initial operant motor/performance in LHSS in a dose dependent fashion. Microinjections of the normally ineffective low dose of DALA (2.5 micrograms/microliters) following accumbens 6-OHDA treatment produced a significant LHSS reward decrease 2 weeks post-treatment, while LHSS motor/performance was relatively unaffected. Results are discussed in terms of opiate-dopamine and limbic-motor interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855230     DOI: 10.1007/bf02244999

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  Dopamine denervation of the nucleus accumbens induces a selective increase in the number of delta-opioid binding sites.

Authors:  E Esposito; L Cervo; P Petrillo; M Sbacchi; A Tavani; R Samanin
Journal:  Brain Res       Date:  1987-12-08       Impact factor: 3.252

2.  6-Hydroxydopamine lesions of the nucleus accumbens, but not of the caudate nucleus, attenuate enhanced responding with reward-related stimuli produced by intra-accumbens d-amphetamine.

Authors:  J R Taylor; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Blockade of dopamine receptors reverses the behavioral effects of endogenous enkephalins in the Nucleus caudatus but not in the Nucleus accumbens: differential involvement of delta and mu opioid receptors.

Authors:  V Daugé; P Rossignol; B P Roques
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Psychomotor stimulant properties of addictive drugs.

Authors:  R A Wise
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Increased food intake after opioid microinjections into nucleus accumbens and ventral tegmental area of rat.

Authors:  R F Mucha; S D Iversen
Journal:  Brain Res       Date:  1986-11-12       Impact factor: 3.252

6.  Reward produced by microinjection of (D-Ala2),Met5-enkephalinamide into the ventral tegmental area.

Authors:  A G Phillips; F G LePiane
Journal:  Behav Brain Res       Date:  1982-06       Impact factor: 3.332

7.  Reinforcing effects of brain microinjections of morphine revealed by conditioned place preference.

Authors:  D van der Kooy; R F Mucha; M O'Shaughnessy; P Bucenieks
Journal:  Brain Res       Date:  1982-07-08       Impact factor: 3.252

8.  Feeding induced by ventricular bromocriptine and amphetamine: a possible excitatory role for dopamine in eating behavior.

Authors:  K R Evans; R Eikelboom
Journal:  Behav Neurosci       Date:  1987-08       Impact factor: 1.912

9.  Conditioned place preference from intra-accumbens but not intra-caudate amphetamine injections.

Authors:  G D Carr; N M White
Journal:  Life Sci       Date:  1983-12-19       Impact factor: 5.037

10.  Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective mu and delta opioid peptides or kelatorphan an inhibitor of enkephalin-degrading-enzymes.

Authors:  V Daugé; P Rossignol; B P Roques
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.